TRGNF (Transgene) Cash-to-Debt : 170.01 (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Transgene Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Transgene's cash to debt ratio for the quarter that ended in Jun. 2024 was 170.01.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Transgene could pay off its debt using the cash in hand for the quarter that ended in Jun. 2024.

The historical rank and industry rank for Transgene's Cash-to-Debt or its related term are showing as below:

TRGNF' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.43 Med: 1.94 Max: 170.22
Current: 170.22

During the past 13 years, Transgene's highest Cash to Debt Ratio was 170.22. The lowest was 0.43. And the median was 1.94.

TRGNF's Cash-to-Debt is ranked better than
81.42% of 1491 companies
in the Biotechnology industry
Industry Median: 6.4 vs TRGNF: 170.22

Transgene Cash-to-Debt Historical Data

The historical data trend for Transgene's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Transgene Cash-to-Debt Chart

Transgene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.60

4.99

12.90

10.95

12.46

Transgene Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Cash-to-Debt	Get a 7-Day Free Trial															13.38	10.95	3.99	12.46	170.01

Competitive Comparison of Transgene's Cash-to-Debt

For the Biotechnology subindustry, Transgene's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Transgene's Cash-to-Debt falls into.

Transgene Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Transgene's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	17.084	/	(1.352	+	0.019)
	=	12.46

Transgene's Cash to Debt Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	16.491	/	(0.097	+	0)
	=	170.01

Transgene (OTCPK:TRGNF) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Transgene Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Transgene's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (OTCPK:TRGNF) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

0OCQ:UK TNG:France TGNA:Germany

Address

400 Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company. The Company conducts its business exclusively in the clinical research and development of therapeutic vaccines and immunotherapeutic products. The company's clinical-stage programs are TG4010 for non-small cell lung cancer and Pexa-vec for liver cancer. Its product pipeline includes TG4001, TG1050, TG6002 etc. It is engaged in clinical research and development of therapeutic vaccines and immunotherapeutic products. The majority of its operations is located in France.